View Future GrowthZenith Capital 過去の業績過去 基準チェック /06Zenith Capitalの収益は年間平均-1.8%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 92.7%割合で 増加しています。主要情報-1.79%収益成長率1.38%EPS成長率Biotechs 業界の成長17.04%収益成長率92.70%株主資本利益率n/aネット・マージン-1,531.20%前回の決算情報31 Jan 2026最近の業績更新お知らせ • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020すべての更新を表示Recent updatesお知らせ • Aug 05Zenith Capital Corp., Annual General Meeting, Oct 26, 2023Zenith Capital Corp., Annual General Meeting, Oct 26, 2023.お知らせ • Aug 13Zenith Capital Corp., Annual General Meeting, Oct 27, 2022Zenith Capital Corp., Annual General Meeting, Oct 27, 2022. Location: Calgary, AB Calgary Canadaお知らせ • May 12Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical TrialZenith Epigenetics Ltd. announced the initiation of a Phase 2b Triple Negative Breast Cancer clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease. In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly polymerase inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.お知らせ • Feb 01+ 1 more updateZenith Epigenetics Provides Clinical UpdateZenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC. Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.お知らせ • Jun 25Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate CancerZenith Capital Corp. announced the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal. The study demonstrated that mCRPC, when treated with ARSi, can switch its lineage from adenocarcinoma to a more aggressive neuroendocrine type which is less dependent on androgen receptor signaling. This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes. ZEN-3694 inhibits BRD4 and E2F1 which epigenetically regulate this lineage switch. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found. Furthermore, this was supported by clinical data from ZEN-3694 Phase 1b/2a mCRPC study which showed that ZEN-3694 was most effective in patients whose tumors were less dependent on androgen receptor signaling and did not respond to prior ARSi. High expression of BRD4 and E2F1 were also observed in the tumors of two patients with treatment emergent neuroendocrine prostate cancer, and both patients had a response to ZEN-3694 + enzalutamide, consistent with the role of ZEN-3694 in overcoming resistance to ARSi in this aggressive form of prostate cancer.お知らせ • Mar 17Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor KeytrudaZenith Epigenetics Ltd. announced the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company's lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to 1st a 1 line ARSI therapy. These patients have a very poor prognosis and have a significant need for non-chemotherapies. This study is being supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.お知らせ • Oct 06Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology IndicationsZenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.お知らせ • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020お知らせ • Jul 19+ 3 more updatesZenith Capital Corp. Auditor Raises 'Going Concern' DoubtZenith Capital Corp. filed its Annual on Aug 25, 2014 for the period ending Apr 30, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.収支内訳Zenith Capital の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:ZHCL.F 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Jan 261-82231 Oct 251-72231 Jul 251-72330 Apr 251-72331 Jan 250-72331 Oct 240-82431 Jul 240-92530 Apr 240-112731 Jan 240-1721231 Oct 230-1621131 Jul 230-1531030 Apr 230-133831 Jan 230-73431 Oct 220-73431 Jul 220-73430 Apr 220-83431 Jan 220-83431 Oct 210-83431 Jul 210-73530 Apr 210-72531 Jan 210-82531 Oct 200-92631 Jul 200-102630 Apr 200-102731 Jan 200-123931 Oct 190-112831 Jul 190-113930 Apr 190-113831 Jan 190-102731 Oct 180-102831 Jul 180-82730 Apr 180-92731 Jan 180-82731 Oct 170-72631 Jul 170-82630 Apr 170-72631 Jan 170-72631 Oct 160-72631 Jul 160-72630 Apr 160-82631 Jan 160-92631 Oct 150-737質の高い収益: ZHCL.Fは現在利益が出ていません。利益率の向上: ZHCL.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ZHCL.Fは利益が出ておらず、過去 5 年間で損失は年間1.8%の割合で増加しています。成長の加速: ZHCL.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: ZHCL.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: ZHCL.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 20:40終値2026/05/22 00:00収益2026/01/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zenith Capital Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020
お知らせ • Aug 05Zenith Capital Corp., Annual General Meeting, Oct 26, 2023Zenith Capital Corp., Annual General Meeting, Oct 26, 2023.
お知らせ • Aug 13Zenith Capital Corp., Annual General Meeting, Oct 27, 2022Zenith Capital Corp., Annual General Meeting, Oct 27, 2022. Location: Calgary, AB Calgary Canada
お知らせ • May 12Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical TrialZenith Epigenetics Ltd. announced the initiation of a Phase 2b Triple Negative Breast Cancer clinical trial combining ZEN-3694 + Pfizer Inc.'s Talzenna (talazoparib). The trial will continue to evaluate the efficacy and safety of this combination in patients with locally advanced or metastatic germline wild type BRCA1/2 TNBC. This Phase 2b trial is an extension of the recently completed Phase 1b/2 trial which met its primary efficacy endpoint of clinical benefit rate comprised of objective responses plus stable disease and which showed that the combination regimen was well tolerated. The Phase 2b extension will enroll patients who have previously been treated with a TROP2 antibody drug conjugate for locally advanced or metastatic disease. In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a poly polymerase inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. Single agent PARPi are approved for gBRCAm HER2-negative locally advanced or metastatic breast cancer, as both PARP inhibition and non-functioning DNA repair proteins BRCA1/2 are required to block DNA repair and kill tumor cells (synthetic lethality). Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.
お知らせ • Feb 01+ 1 more updateZenith Epigenetics Provides Clinical UpdateZenith Capital Corp. is developing various novel combinations of BET inhibitors with other targeted agents for numerous oncology indications in pre-selected or enriched patient populations. Company lead compound, ZEN-3694 is undergoing clinical development in multiple clinical trials: Phase 2b metastatic castration resistant prostate (mCRPC) cancer trialin combination with androgen receptor inhibitor, XTANDI (enzalutamide): Randomized trial comparing XTANDI in combination with ZEN-3694 to XTANDI treatment alone in patients with mCRPC. Conducted in collaboration Astellas Pharma and Newsoara Biopharma. This study is active and currently recruiting across multiple sites in the US and is in the activation stage in China. Differentiated study that will focus on addressing a significant unmet need in patients with AR independent tumors. Phase 2b Triple Negative Breast Cancer (TNBC) trial in combination with the PARP inhibitor TALZENNA (talazoparib): Conducted in collaboration with Pfizer and Newsoara Biopharma. This study is an expansion of the ongoing Phase 2 trial and is in the activation stage in US/EU/China. Based on discussions with US FDA, this Phase 2b trial – with a positive outcome – can potentially enable registration of ZEN-3694 via accelerated approval. Phase 1b/2 androgen receptor independent mCRPC trial in combination with immune checkpoint inhibitor KEYTRUDA (pembrolizumab) and XTANDI: Conducted in collaboration with Merck, the University of California, San Francisco, and the University of Michigan. Data to date shows that the combination can be dosed safely and is clinically active. The trial has progressed to the efficacy stage and is accruing well. Phase 1b/2 ovarian cancer trial in combination with immune-checkpoint inhibitors, nivolumab and ipilimumab: National Cancer Institute is conducting this trial in collaboration with Zenith and BMS. This is a second trial combining immune-checkpoint inhibitors with ZEN-3694. Expected to enroll first patient in the first quarter of 2022. Phase 1b/2 solid tumors and lymphoma trial in combination with entinostat: National Cancer Institute is conducting this trial in collaboration with Zenith and SyndaxExpected to enroll first patient in the first half of 2022.
お知らせ • Jun 25Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate CancerZenith Capital Corp. announced the publication of an important study which has uncovered the role of ZEN-3694, a BET bromodomain inhibitor (BETi), in overcoming the resistance of metastatic castration resistant prostate cancer (mCRPC) to androgen receptor signaling inhibitors (ARSi). The study, led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal. The study demonstrated that mCRPC, when treated with ARSi, can switch its lineage from adenocarcinoma to a more aggressive neuroendocrine type which is less dependent on androgen receptor signaling. This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes. ZEN-3694 inhibits BRD4 and E2F1 which epigenetically regulate this lineage switch. Blocking BET bromodomain proteins in cell models stopped the activation of this program that drives the development of neuroendocrine prostate tumors, the research team found. Furthermore, this was supported by clinical data from ZEN-3694 Phase 1b/2a mCRPC study which showed that ZEN-3694 was most effective in patients whose tumors were less dependent on androgen receptor signaling and did not respond to prior ARSi. High expression of BRD4 and E2F1 were also observed in the tumors of two patients with treatment emergent neuroendocrine prostate cancer, and both patients had a response to ZEN-3694 + enzalutamide, consistent with the role of ZEN-3694 in overcoming resistance to ARSi in this aggressive form of prostate cancer.
お知らせ • Mar 17Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor KeytrudaZenith Epigenetics Ltd. announced the dosing of first patient with a triple combination of ZEN-3694 + Merck's immune check point inhibitor, KEYTRUDA, + Pfizer's androgen receptor signaling inhibitor (ARSI), XTANDI, in a University of California, San Francisco (UCSF) investigator led metastatic castration resistant prostate cancer (mCRPC) Phase 2 clinical trial. ZEN-3694, the Company's lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications. This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to 1st a 1 line ARSI therapy. These patients have a very poor prognosis and have a significant need for non-chemotherapies. This study is being supported in part by a research grant from the Investigator-Initiated Studies Program of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
お知らせ • Oct 06Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology IndicationsZenith Epigenetics Ltd. announced the execution of a cooperative research and development agreement with the National Cancer Institute to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb to investigate the combination of Zenith’s epigenetic therapy BET inhibitor ZEN-3694 with immuno-oncology therapies – checkpoint inhibitors nivolumab and ipilimumab – in resistant ovarian cancer.
お知らせ • Oct 04Zenith Capital Corp. to Report Fiscal Year 2020 Results on Oct 12, 2020Zenith Capital Corp. announced that they will report fiscal year 2020 results on Oct 12, 2020
お知らせ • Jul 19+ 3 more updatesZenith Capital Corp. Auditor Raises 'Going Concern' DoubtZenith Capital Corp. filed its Annual on Aug 25, 2014 for the period ending Apr 30, 2014. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.